Details
Stereochemistry | RACEMIC |
Molecular Formula | C8H19NO.ClH |
Molecular Weight | 181.703 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(N)CCCC(C)(C)O
InChI
InChIKey=JZNBMCOSOXIZJB-UHFFFAOYSA-N
InChI=1S/C8H19NO.ClH/c1-7(9)5-4-6-8(2,3)10;/h7,10H,4-6,9H2,1-3H3;1H
Heptaminol is an amino alcohol that has been used as a myocardial stimulant and vasodilator and to relieve bronchospasm. Its most common therapeutic use is in orthostatic hypotension. The mechanism of heptaminol's therapeutic actions is not well understood although it has been suggested to affect catecholamine release or calcium metabolism.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2366456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22761000 |
15.3 µM [IC50] | ||
Target ID: GO:0051620 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2386550 |
60.0 µM [Ki] | ||
Target ID: GO:0090493 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2386550 |
650.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Corasore Approved UseIs for the treatment of hypotension, fainting tendency and slight to moderately severe circulatory collapse; Asthenia, nervous and physical fatigue in general and sporting medicine; Adjuvant treatment of mild and moderate cases of heart failure particularly
incipient pulmonary edema; Heart failure associated with toxic, infectious, degenerative orarteriosclerotic myocardial disease; Neonatal asphyxia. |
PubMed
Title | Date | PubMed |
---|---|---|
Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians. | 1990 |
|
Heptaminol interferes in the AxSYM FPIA amphetamine/methamphetamine II assay. | 2001 Aug |
|
Clinical study of the Ginko biloba--Troxerutin-Heptaminol Hce in the treatment of acute hemorrhoidal attacks. | 2004 Feb |
|
Metabolism of isometheptene in human urine and analysis by gas chromatography-mass spectrometry in doping control. | 2005 Dec 5 |
|
Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. | 2005 Jul |
|
Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure. | 2005 Sep |
|
Solid-phase column chromatographic and gas chromatographic-mass spectrometric determination of heptaminol in human urine and related pharmacokinetic profiles. | 2006 Jul-Aug |
|
Hair lightening in an hemodialysis patient treated by heptaminol (heptamyl). | 2009 Apr 15 |
Patents
Sample Use Guides
Infants & children under 12 years: 4-16 drops (25 -100 mg) depending on
age, 2 – 4 times daily, up to 6 times daily if necessary, or as directed by the physician.
Adults & children over 12 years: One tablet or 25 drops, (150 mg) 2-4 times daily, up to 6 times daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1422567
1. The effects of heptaminol on calcium current amplitude and characteristics were studied in single ventricular myocytes of guinea-pig by use of the whole cell configuration of the patch clamp technique. 2. A concentration-dependent decrease in ICa amplitude was observed. At heptaminol concentration as low as 10(-6) M, this effect was observed in only two cells (n = 6). At 10(-5) M the reduction of ICa was of 30 +/- 15% (n = 11). Both at -40 mV and -80 mV HP, heptaminol (10(-5) M) significantly increased the steady state inactivation of ICa.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB02489MIG
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL2111076
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY | |||
|
DTXSID9045891
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY | |||
|
10969
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY | |||
|
543-15-7
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY | |||
|
XB3RM40HIR
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY | |||
|
758406
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY | |||
|
208-837-5
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY | |||
|
m5962
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
236294
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000091718
Created by
admin on Sat Dec 16 07:38:23 GMT 2023 , Edited by admin on Sat Dec 16 07:38:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD